Doctor Reviews Growth Hormone vs Peptides - Which Should You Take?!

Summary

Dr. Jones compares human growth hormone (HGH) with growth-hormone-releasing peptides. He argues that HGH has much stronger clinical-trial evidence for body-composition changes, while peptides may be a more practical choice for some people based on their reported side-effect profile, cost, and prescribing context.

Evidence and trade-offs

• The speaker says HGH has decades of randomized-trial evidence. Studies in adults with diagnosed growth hormone deficiency found changes in fat and lean mass over 6–12 months.
• He says evidence for popular peptides such as CJC-1295 and ipamorelin is much more limited for human body-composition outcomes. He identifies tesamorelin as an exception, citing its approval for HIV-related visceral fat.
• He stresses that raising growth hormone does not, by itself, prove that a peptide will produce the same results as HGH.
• He describes HGH-related concerns including swelling, carpal tunnel symptoms, joint pain, insulin resistance, and—particularly with high doses—organ or heart enlargement.
• He says peptides can also cause side effects, including injection-site reactions, headaches, and temporary water retention. He cautions that peptides can affect the body’s own hormone regulation and rejects the claim that they cannot suppress natural growth hormone production.

Decision framework described in the video

The speaker says treatment decisions should weigh:

• The strength of evidence for the specific treatment and goal.
• Potential side effects and the need for medical monitoring.
• Cost and whether treatment is sustainable.
• Whether foundational health factors have been addressed first.
• Whether a diagnosed medical condition warrants HGH treatment.

Peptides discussed

• Tesamorelin: Described as the peptide option with the strongest evidence and an adult FDA-approved use, though the speaker notes that it can be expensive.
• CJC-1295 without DAC plus ipamorelin: Presented as the clinic’s commonly used combination. These are the speaker’s clinical opinions, not a recommendation for viewers to use them.
• Sermorelin: Described as a longer-established, more conservative option.
• CJC-1295 with DAC: The speaker advises against it, saying its long-lasting effect does not preserve the short, pulse-like pattern he prefers.
• MK-677 (ibutamoren): He cautions that it may increase appetite and insulin resistance, and may increase both fat and muscle mass.
• GHRP-2 and GHRP-6: He says these may affect cortisol and prolactin and increase appetite.

Foundations and self-care priorities

Before considering peptides, the speaker recommends addressing:

• Sleep quality and duration.
• Insulin resistance and other metabolic concerns.
• Nutrition and adequate intake to support goals.
• Testosterone or other relevant hormone issues, assessed with a clinician.
• General lifestyle factors and appropriate lab monitoring.

His central point is that peptides should not be used as a substitute for these foundations. He says people with diagnosed growth hormone deficiency or certain pituitary conditions require specialist medical care; optimization goals alone do not establish a need for HGH or peptides.

Safety

• The speaker warns against ordering peptides online or using products without appropriate medical oversight.
• He discusses concerns about product contamination, incorrect labeling, inconsistent dosing, and immune reactions. Monitoring may include IGF-1, glucose, and insulin.
• The discussion is educational and does not replace individualized medical advice. Decisions about hormones or peptides should be made with a qualified healthcare professional.

Presenter and sources mentioned

• Presenter: Dr. Jones, DC.
• Sources referenced in the video: Clinical trials on HGH and growth-hormone-related treatments; FDA approvals and regulatory actions; an unnamed Belgian study of black-market peptide samples; and the speaker’s clinic experience and patient reports. No specific study titles or authors are provided in the subtitles.